China Finalizes BCI Data Standards for Medical Devices
China's latest regulatory move establishes a unified framework for AI-driven brainwave data, targeting a market projected to reach 840 million dollars by 2028.
China has approved its third national standard for brain-computer interface (BCI) medical devices, marking a shift toward systematic regulation of the sector. The new guideline, effective September 1, 2027, is the world’s first to mandate specific requirements for AI algorithms used in processing brainwave data. This regulatory step creates a uniform baseline for how neural data is collected, labeled, and stored, removing the fragmented approach that previously hindered interoperability and clinical validation.
The standard complements two earlier frameworks released in 2025, which defined technical terminology and testing methods for implantable stimulators. According to Li Shu, a drafter of the standard from the National Institutes for Food and Drug Control, this new rule provides the necessary data quality foundation for registration reviews. By standardizing the data pipeline, the regulation reduces uncertainty for manufacturers seeking to bring AI-enhanced neurotech products to market, directly impacting their ability to secure regulatory clearance.
Regulatory Pathway Accelerates Product Launches
The National Medical Products Administration (NMPA) has integrated implantable BCIs into its priority examination catalogue for high-end medical devices. This designation guides enterprises through streamlined registration applications, while selected products gain access to innovation and "global new" green channels. Yuan Peng, Deputy Director of the Medical Device Registration Department at the NMPA, confirmed that full-process guidance is being provided to accelerate product launch. This administrative support lowers the time-to-market barrier, a critical factor for companies competing in the fast-evolving neurotechnology space.
Market Growth Driven by Standardization
Industry data projects China’s BCI market will exceed 6 billion yuan, approximately 840 million US dollars, by 2028. This growth is expected to follow a compound annual rate of 17.7 percent from 2024 to 2028. The global context is similarly robust, with forecasts indicating the BCI medical application market will reach 40 billion US dollars by 2030 and 145 billion US dollars by 2040. The establishment of clear standards serves as a catalyst for this expansion, providing the regulatory certainty required for large-scale commercial investment.
Comprehensive Framework for Neural Signal Processing
The NMPA is currently developing a broader suite of standards, including ten national and three industry-specific guidelines. These efforts cover the entire lifecycle of BCI devices, from paradigm design and neural signal decoding to reliability verification. As reported by GN auto stocks/healthcare: medical device, this systematic approach aims to create a cohesive ecosystem. By defining precise metrics for signal acquisition and performance testing, the regulation ensures that devices meet consistent safety and efficacy benchmarks, thereby enhancing investor and consumer confidence in the technology.
